Your introduction to

INJECTION
Zirabev®
bevacizumab-bvzr

Pfizer

SELECTED SAFETY INFORMATION

Possible serious side effects

Everyone reacts differently to ZIRABEV therapy, so it's important to know what the side effects are. ZIRABEV may cause serious side effects that can be life-threatening. Your doctor will stop treatment if any serious side effects occur. **Be sure to contact your health care team if there are any signs of these side effects.**

Most serious side effects (not common, but sometimes fatal):

- **GI perforation**. A hole that develops in your stomach or intestine. Symptoms include pain in your abdomen, nausea, vomiting, constipation, or fever
- **Wounds that don't heal**. A cut made during surgery can be slow to heal or may not fully heal. Do not undergo surgery without first discussing this potential risk with your doctor
- **Serious bleeding**. This includes vomiting or coughing up blood; bleeding in the stomach, brain, or spinal cord; nosebleeds; and vaginal bleeding. If you recently coughed up blood or had serious bleeding, be sure to tell your doctor

Please see Important Safety Information on pages 6-7 and full Prescribing Information at ZIRABEV.com.

INJECTION
Zirabev®
bevacizumab-bvzr
Pfizer

What is ZIRABEV?

ZIRABEV (bevacizumab-bvzr) is an FDA-approved biosimilar* to Avastin® (bevacizumab).

ZIRABEV is FDA approved to help treat:

Metastatic Colorectal Cancer (mCRC)

ZIRABEV is approved to treat mCRC for:

- First- or second-line treatment in combination with intravenous fluorouracil-based chemotherapy
- Second-line treatment when used with fluoropyrimidine-based (combined with irinotecan or oxaliplatin) chemotherapy after cancer progresses following a first-line treatment that includes a bevacizumab product

ZIRABEV is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body.

Non-Small Cell Lung Cancer (NSCLC)

ZIRABEV, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous NSCLC in people who have not received chemotherapy for their advanced disease.

Recurrent Glioblastoma (GBM)

ZIRABEV is approved to treat GBM in adult patients whose cancer has progressed after prior treatment (recurrent or rGBM).

Metastatic Renal Cell Carcinoma (mRCC)

ZIRABEV, used with interferon alfa, is approved to treat mRCC.

Advanced Cervical Cancer (CC)

ZIRABEV, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix.

Ovarian Cancer (OC)

ZIRABEV is approved to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer:

- In combination with carboplatin and paclitaxel, followed by ZIRABEV alone, for the treatment of patients with advanced (stage III or IV) disease following initial surgery
- In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, for platinum-resistant recurrent disease in women who received no more than 2 prior chemotherapy treatments
- Either in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine, followed by ZIRABEV alone, for patients with platinum-sensitive recurrent disease

Please see Important Safety Information on pages 6-7 and full Prescribing Information at ZIRABEV.com.

What are biosimilars?

Biosimilars are highly similar to the original biologics. Although it is impossible to produce an identical copy of a biologic medicine, a biosimilar must be proven to show no clinically meaningful differences from a reference product.

Do biosimilars have the same side effects and safety profile as the reference products?

Biosimilars must demonstrate that they have no clinically meaningful differences from their reference products in terms of safety and effectiveness. They are expected to work the same way as the original medicines.

How long have biosimilars been available?

The first biosimilar was approved in the United States in 2015.

How will I receive ZIRABEV?

ZIRABEV is given by a health care provider as an intravenous (IV) infusion. That means you get ZIRABEV through a needle in your vein.

If you've had surgery you cannot receive ZIRABEV until at least 28 days following surgery and the wound is fully healed.

*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar and the reference product.

SELECTED SAFETY INFORMATION

Other possible serious side effects:

- **Abnormal passage in the body.** This type of passage—known as a fistula—is an irregular connection from one part of the body to another and can sometimes be fatal
- **Severe high blood pressure.** Blood pressure that severely spikes or shows signs of affecting the brain. Blood pressure should be monitored every 2 to 3 weeks while on ZIRABEV and after stopping treatment
- **Kidney problems.** These may be caused by too much protein in the urine and can sometimes be fatal
- **Infusion-related reactions.** These were uncommon with the first dose of bevacizumab (less than 3% of patients); 0.4% of patients had severe reactions. Infusion reactions include high blood pressure or severe high blood pressure that may lead to stroke, trouble breathing, decreased oxygen in red blood cells, a serious allergic reaction, chest pain, headache, tremors, and excessive sweating. Your doctor or nurse will monitor you for signs of infusion reactions
- **Severe stroke or heart problems.** These may include blood clots, mini-stroke, heart attack, chest pain, and your heart may become too weak to pump blood to other parts of your body (congestive heart failure). These can sometimes be fatal
- **Nervous system and vision problems.** Signs include headache, seizure, high blood pressure, sluggishness, confusion, and blindness

INJECTION
Zirabev®
bevacizumab-bvzr
Pfizer

What do I need to know about taking ZIRABEV?

There are some side effects that may require you to stop ZIRABEV. But as long as your side effects remain manageable and your cancer is under control, your doctor may advise you to keep taking ZIRABEV.

What can I expect from my infusion?

Your doctor or nurse will monitor you for signs of infusion reactions and may stop ZIRABEV treatment if severe reactions occur. Reactions can include high blood pressure or severe high blood pressure that may lead to stroke, trouble breathing, decreased oxygen in red blood cells, a serious allergic reaction, chest pain, headache, tremors, and excessive sweating.

How long do I take ZIRABEV?

Depending on your type of cancer, your doctor may prescribe ZIRABEV with or without chemotherapy. Your doctor may continue prescribing ZIRABEV as long as your disease is controlled and your side effects are manageable.

If your cancer progresses, your doctor will evaluate whether you should continue treatment with ZIRABEV.

How often will I receive ZIRABEV?



Depending on your specific type of cancer, you may receive ZIRABEV every 2 to 3 weeks with or without additional treatment you may be prescribed.

If you have questions about how often you'll receive ZIRABEV, speak with your health care team.

If your ZIRABEV infusions are tolerated:

1st infusion | 2nd infusion | 3rd and future infusions

NOTE: You always get the same dosage of ZIRABEV. If your ZIRABEV infusions are tolerated, they can take as little as 30 minutes.

SELECTED SAFETY INFORMATION

Side effects seen most often

In clinical studies across different types of cancer, some patients treated with bevacizumab experienced the following side effects:

- High blood pressure
- Too much protein in the urine
- Nosebleeds
- Bleeding
- Back pain
- Headache
- Taste change
- Dry skin
- Inflammation of the skin
- Inflammation of the nose
- Watery eyes

Please see Important Safety Information on pages 6-7 and full Prescribing Information at ZIRABEV.com.

SELECTED SAFETY INFORMATION

ZIRABEV is not for everyone.

Talk to your doctor if you are:

- **Undergoing surgery.** ZIRABEV should not be used for at least 28 days before or after surgery, and until surgical wounds are fully healed
- **Pregnant, think you are pregnant, planning to become pregnant, or breastfeeding.** Data have shown that bevacizumab products may harm your unborn baby. Use birth control while on ZIRABEV. If you stop ZIRABEV, you should keep using birth control for 6 months before trying to become pregnant. Taking bevacizumab products could cause a woman's ovaries to stop working and may impair her ability to have children. Breastfeeding while on bevacizumab products may harm your baby, therefore women should not breastfeed during and for 6 months after taking ZIRABEV

What should I tell my doctor before receiving ZIRABEV?

Talk to your doctor if you are:

Undergoing surgery

ZIRABEV should not be used for 28 days before or after surgery and until surgical wounds are fully healed.

Pregnant or think you are pregnant

Data have shown that bevacizumab products may harm your unborn baby. Use birth control while on ZIRABEV. If you stop ZIRABEV, you should keep using birth control for 6 months before trying to become pregnant.

Planning to become pregnant

Taking bevacizumab products could cause a woman's ovaries to stop working and may impair her ability to have children.

Breastfeeding

Breastfeeding while on bevacizumab products may harm your baby and is therefore not recommended during and for 6 months after taking ZIRABEV.

What are the possible serious side effects of ZIRABEV?

Everyone reacts differently to ZIRABEV therapy, so it's important to know what the side effects are.

ZIRABEV may cause serious side effects that can be life-threatening. Your doctor will stop treatment if any serious side effects occur.

Be sure to contact your health care team if there are any signs of these side effects.

Most serious side effects (not common, but sometimes fatal) include:

GI perforation and fistulae

A hole that develops in your stomach or intestine. Symptoms include pain in your abdomen, nausea, vomiting, constipation, or fever.

The development of an abnormal passageway between 2 organs (fistula). Symptoms may vary depending on location and organs involved.

Wounds that don't heal

A cut made during surgery can be slow to heal or may not fully heal. Do not undergo surgery without first discussing this potential risk with your doctor.

Serious bleeding

This includes vomiting or coughing up blood; bleeding in the stomach, brain, or spinal cord; nosebleeds; and vaginal bleeding. If you have recently coughed up blood or had serious bleeding, be sure to tell your doctor.

Please see Important Safety Information on pages 6-7 and full Prescribing Information at ZIRABEV.com.

What financial support may be available for my ZIRABEV prescription?

At Pfizer Oncology Together™, we treat your individual needs as a priority. We'll help you identify financial assistance options so you can get your prescribed ZIRABEV, regardless of your insurance coverage: commercial, Medicare/government issued, or uninsured.

Eligible patients may pay as little as $0 per treatment

- Pfizer Oncology Together Co-Pay Savings Program for Injectables
  - Eligible,* commercially insured patients† may pay as little as $0 per treatment for ZIRABEV, regardless of income.‡ Limits, terms, and conditions apply

FOR LIVE, PERSONALIZED SUPPORT

Call **1-877-744-5675** (Monday–Friday 8 AM–8 PM ET) or Visit **PfizerOncologyTogether.com**

***Terms and Conditions:** By using this program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

The Pfizer Oncology Together Co-Pay Savings Program for Injectables for ZIRABEV® is not valid for patients who are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as "La Reforma de Salud"). Program offer is not valid for cash-paying patients. Patients prescribed ZIRABEV for hepatocellular carcinoma are not eligible for this co-pay savings program. With this program, eligible patients may pay as little as $0 co-pay per ZIRABEV treatment, subject to a maximum benefit of $25,000 per calendar year for out-of-pocket expenses for ZIRABEV including co-pays or coinsurances. The amount of any benefit is the difference between your co-pay and $0. After the maximum of $25,000 you will be responsible for the remaining monthly out-of-pocket costs. Patient must have private insurance with coverage of ZIRABEV. This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plans or other private health or pharmacy benefit programs. You must deduct the value of this assistance from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf. You are responsible for reporting use of the program to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the program, as may be required. You should not use the program if your insurer or health plan prohibits use of manufacturer co-pay assistance programs. This program is not valid where prohibited by law. This program cannot be combined with any other savings, free trial or similar offer for the specified prescription. **Co-pay card will be accepted only at participating pharmacies. This program is not health insurance.** This program is good only in the U.S. and Puerto Rico. This program is limited to 1 per person during this offering period and is not transferable. No other purchase is necessary. Data related to your redemption of the program assistance may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer's programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other assistance redemptions and will not identify you. Pfizer reserves the right to rescind, revoke or amend this program without notice. This program may not be available to patients in all states. For more information about Pfizer, visit www.pfizer.com. For more information about the Pfizer Oncology Together Co-Pay Savings Program for Injectables, visit pfizeroncologytogether.com, call 1-877-744-5675, or write to Pfizer Oncology Together Co-Pay Savings Program for Injectables, P.O. Box 220366, Charlotte, NC 28222. Program terms and offer will expire at the end of each calendar year. Before the calendar year ends, you will receive information and eligibility requirements for continued participation.

Are any other patient support resources available?

At Pfizer Oncology Together, our Care Champions, who have social work experience, can provide you resources that may help with some of your day-to-day challenges[§]:

Connections to emotional support resources

Connections to independent organizations that help eligible patients find free rides and lodging for treatment-related appointments

Educational information about physical and mental health, nutrition, and ZIRABEV

Information to help you prepare for leaving or returning to work

†For patients to be eligible for the Injectables Co-Pay Program for ZIRABEV, they must have commercial insurance that covers ZIRABEV and they cannot be enrolled in a state or federally funded insurance program. Whether a co-pay expense is eligible for the Injectables Co-Pay Program for ZIRABEV benefit will be determined at the time the benefit is paid. Co-pay expenses must be in connection with a separately paid claim for ZIRABEV administered in the outpatient setting.

‡The Injectables Co-Pay Program for ZIRABEV will pay the co-pay for ZIRABEV up to the annual assistance limit of $25,000 per calendar year per patient.

§Some services are provided through third-party organizations that operate independently and are not controlled by Pfizer. Availability of services and eligibility requirements are determined solely by these organizations.

Please see Important Safety Information on pages 6-7 and full Prescribing Information at ZIRABEV.com.

Is there a digital resource that can help me keep track of my cancer care?

A free app designed to help manage life with cancer

LIVINGWITH™

Whether you're living with cancer or want to support someone who is, **LivingWith™**, a free app developed by Pfizer Oncology, may help you stay connected and organized, all in one place.

Visit ThisIsLivingWithCancer.com to learn more. Available in English and Spanish. Download **LivingWith** for free.

Download on the App Store GET IT ON Google Play

The free resources offered through **This Is Living With Cancer™** and **LivingWith™** are available to anyone living with cancer and their loved ones, and are not specific to ZIRABEV.

App Store is a service mark of Apple Inc., registered in the U.S. and other countries. Google Play and the Google Play logo are trademarks of Google LLC.

IMPORTANT SAFETY INFORMATION

Possible serious side effects

Everyone reacts differently to ZIRABEV therapy, so it's important to know what the side effects are. ZIRABEV may cause serious side effects that can be life-threatening. Your doctor will stop treatment if any serious side effects occur. **Be sure to contact your health care team if there are any signs of these side effects.**

Most serious side effects (not common, but sometimes fatal):

- **GI perforation**. A hole that develops in your stomach or intestine. Symptoms include pain in your abdomen, nausea, vomiting, constipation, or fever
- **Wounds that don't heal**. A cut made during surgery can be slow to heal or may not fully heal. Do not undergo surgery without first discussing this potential risk with your doctor
- **Serious bleeding**. This includes vomiting or coughing up blood; bleeding in the stomach, brain, or spinal cord; nosebleeds; and vaginal bleeding. If you recently coughed up blood or had serious bleeding, be sure to tell your doctor

Other possible serious side effects:

- **Abnormal passage in the body.** This type of passage—known as a fistula—is an irregular connection from one part of the body to another and can sometimes be fatal
- **Severe high blood pressure.** Blood pressure that severely spikes or shows signs of affecting the brain. Blood pressure should be monitored every 2 to 3 weeks while on ZIRABEV and after stopping treatment
- **Kidney problems.** These may be caused by too much protein in the urine and can sometimes be fatal
- **Infusion-related reactions.** These were uncommon with the first dose of bevacizumab (less than 3% of patients); 0.4% of patients had severe reactions. Infusion reactions include high blood pressure or severe high blood pressure that may lead to stroke, trouble breathing, decreased oxygen in red blood cells, a serious allergic reaction, chest pain, headache, tremors, and excessive sweating. Your doctor or nurse will monitor you for signs of infusion reactions
- **Severe stroke or heart problems.** These may include blood clots, mini-stroke, heart attack, chest pain, and your heart may become too weak to pump blood to other parts of your body (congestive heart failure). These can sometimes be fatal
- **Nervous system and vision problems.** Signs include headache, seizure, high blood pressure, sluggishness, confusion, and blindness

Please see additional Important Safety Information on page 7 and full Prescribing Information at ZIRABEV.com.

IMPORTANT SAFETY INFORMATION AND INDICATIONS (CONTINUED)

Side effects seen most often

In clinical studies across different types of cancer, some patients treated with bevacizumab experienced the following side effects:

- High blood pressure
- Too much protein in the urine
- Nosebleeds
- Bleeding
- Back pain
- Headache
- Taste change
- Dry skin
- Inflammation of the skin
- Inflammation of the nose
- Watery eyes

ZIRABEV is not for everyone.

Talk to your doctor if you are:

- **Undergoing surgery.** ZIRABEV should not be used for at least 28 days before or after surgery, and until surgical wounds are fully healed
- **Pregnant, think you are pregnant, planning to become pregnant, or breastfeeding.** Data have shown that bevacizumab products may harm your unborn baby. Use birth control while on ZIRABEV. If you stop ZIRABEV, you should keep using birth control for 6 months before trying to become pregnant. Taking bevacizumab products could cause a woman's ovaries to stop working and may impair her ability to have children. Breastfeeding while on bevacizumab products may harm your baby, therefore women should not breastfeed during and for 6 months after taking ZIRABEV

INDICATIONS

Metastatic Colorectal Cancer

ZIRABEV is approved to treat metastatic colorectal cancer (mCRC) for:

- First- or second-line treatment in combination with intravenous fluorouracil-based chemotherapy
- Second-line treatment when used with fluoropyrimidine-based (combined with irinotecan or oxaliplatin) chemotherapy after cancer progresses following a first-line treatment that includes a bevacizumab product

ZIRABEV is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body.

Please see additional Important Safety Information on page 6 and full Prescribing Information at ZIRABEV.com.

Non-Small Cell Lung Cancer

ZIRABEV, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous non-small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease.

Recurrent Glioblastoma

ZIRABEV is approved to treat glioblastoma (GBM) in adult patients whose cancer has progressed after prior treatment (recurrent or rGBM).

Metastatic Renal Cell Carcinoma

ZIRABEV, used with interferon alfa, is approved to treat metastatic kidney cancer (mRCC).

Persistent, Recurrent, or Metastatic Cervical Cancer

ZIRABEV, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix.

Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

ZIRABEV is approved to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer:

- In combination with carboplatin and paclitaxel, followed by ZIRABEV alone, for the treatment of patients with advanced (stage III or IV) disease following initial surgery
- In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, for platinum-resistant recurrent disease in women who received no more than 2 prior chemotherapy treatments
- Either in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine, followed by ZIRABEV alone, for patients with platinum-sensitive recurrent disease

If you have any questions about your condition or treatment, talk to your doctor.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch. You may also report side effects to Pfizer at 1-800-438-1985.

Your introduction to

INJECTION

Zirabev®

bevacizumab-bvzr

Pfizer

To learn more, please visit ZIRABEV.com

Please see Important Safety Information on pages 6-7 and full Prescribing Information at ZIRABEV.com.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a health care provider. All decisions regarding patient care must be made with a health care provider, considering the unique characteristics of the patient.

The product information provided in this brochure is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

PP-ZIR-USA-0195 May 2021

Pfizer Oncology